Ofatumumab, Methylprednisone, Lenalidomide Regimen Feasible as Frontline Therapy in CLL/SLL

Investigators reported the regimen had a tolerable safety profile, though they said its use may be limited due to the development of newer therapies.

Related Keywords

Sebastian Kaulitzki ,Abbvie Genentech ,Eva Sahakian ,Novartis ,H Lee Moffitt Cancer Center ,Research Institute ,Clinical Lymphoma ,Moffitt Cancer Center ,